Simplification therapy with once-daily didanosine, tenofovir and efavirenz in HIV-1-infected adults with viral suppression receiving a more complex antiretroviral regimen: Final results of the EFADITE trial

Antiviral Therapy

Volumn 10, Issue 7, 2005, Pages 825-832

  Barrios, Ana ^a   Negredo, Eugenia ^b   Domingo, Pere ^c   Estrada, Vicente ^d   Labarga, Pablo ^e   Asensi, Victor ^f   Morales, Dolores ^g   Santos, Jesús ^h   Clotet, Bonaventura ^b   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^e HOSPITAL SAN PEDRO   (Spain)

^f HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^g HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^h HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS ZIDOVUDINE; LIPID; TENOFOVIR;

ARTICLE; CELL COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; DYSLIPIDEMIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PATIENT; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADENINE; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DIDANOSINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; OXAZINES; PHOSPHONIC ACIDS; PROSPECTIVE STUDIES; RNA, VIRAL; TREATMENT OUTCOME;

EID: 27844461529     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Murphy E, Collier A & Kalish L. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Annals of Internal Medicine 2001; 135:17-26.
2. Mocroft A, Ledergerber B, Katlama C, on behalf of EuroSIDA. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. The Lancet 2003; 362:22-29.
3. Yeni P, Hammer S & Hirsch M. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA 2004; 292:251-265.
4. Paterson D, Swindells S & Mohr J. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine 2000; 133:21-30.
5. Mannheimer S, Friedland G, Matts J, Child C, Chesney M, for the Terry Beirn Community Programs for Clinical Research on AIDS. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for HIV-infected persons in clinical trials. Clinical Infectious Diseases 2002; 34:1115-1121.
6. Low-Beer S, Yip B, O'Shaughnessy MV, Hogg R & Montaner J. Adherence to triple therapy and viral load response. Journal of Acquired Immune Deficiency Syndromes 2000; 23:360-361.
7. Sethi A, Celentano D, Gange S, Moore R & Gallant J. Association between adherence to antiretroviral therapy and HIV drug resistance. Clinical Infectious Diseases 2003; 37:1112-1118.
8. Carr A, Samaras K & Thorisdottir A. Diagnosis, prediction, and natural course of HIV-1 protease inhibitor associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. The Lancet 1999; 353:2093-2099.
9. Martinez E, Mocroft A & Garcia-Viejo MA. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. The Lancet 2001; 357:592-598.
10. Mary-Krause M, Cotte L & Simon A. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17:2479-2486.
11. Murphy R & Smith W. Switch studies: a review. HIV Medicine 2002; 3:146-155.
12. Drechsler H & Powderly W. Switching effective antiretroviral therapy: a review. Clinical Infectious Diseases 2002; 35:1219-1230.
13. Barreiro P, Garcia-Benayas T, Soriano V & Gallant J. Simplification of antiretroviral treatment - how to sustain success, reduce toxicity and ensure adherence avoiding PI use. AIDS Reviews 2002; 4:233-241.
14. Martinez E, Arnaiz J & Podzamczer D. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with HIV infection. The New England Journal of Medicine 2003; 349:1036-1046.
15. Hirschel B, Flepp M & Bucher H. Switching from protease inhibitors to efavirenz: differences in efficacy and tolerance among risk groups: a case-control study from the Swiss HIV Cohort. AIDS 2002; 16:381-385.
16. Molina J-M, Journot V & Morand-Joubert L. Simplification therapy with once-daily emtricitabine, didanosine and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: a randomized trial. The Journal of Infectious Diseases 2005; 191:830-839.
17. Hoogewerf M, Regez R, Schouten W, Weigel H, Frissen P & Brinkman K. Change to abacavir-lamivudine-tenofovir combination treatment in patients with HIV-1 who had complete virological suppression. The Lancet 2003; 362:1979-1980.
18. Perez-Elias MJ, Moreno S & Gutierrez C. High virological failure rate in HIV patients after switching to a regimen with two nucleoside reverse transcriptase inhibitors plus tenofovir. AIDS 2005; 19:695-698.
19. th Conference on Retroviruses and Opportunistic Infections. 10-14 February 2003, Boston, MA, USA. Abstract 533.
20. Miners A, Sabin C & Mocroft A. Health-related quality of life in individuals infected with HIV in the era of HAART. HIV Clinical Trials 2001; 2:484-192.
21. Knobel H, Alonso J & Casado J. Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study. AIDS 2002; 16:605-613.
22. Ray A, Olson L & Fridland A. Role of purine nucleoside phosphorylase interactions between 2',3'-dideoxyinosine and allopurinol, ganciclovir or tenofovir. Antimicrobial Agents and Chemotherapy 2004; 48:1089-1095.
23. Pruvost A, Negredo E & Benech H. Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in HIV-infected patients. Antimicrobial Agents and Chemotherapy 2005; 49:1907-1914.
24. th Conference on Retroviruses and Opportunistic Infections. 2-25 February 2005, Boston, MA, USA. Abstract 586.
25. rd Interscience Conference on Antimicrobial Agents and Chemotherapy. 14-17 September 2003, Chicago, USA. Abstract H-1722a.
26. Leon A, Martinez E & Mallolas J. Early virological failure in treatment-naive HIV-infected adults receiving didanosine and tenofovir plus efavirenz or nevirapine. AIDS 2005; 19:213-215.
27. Maitland D, Moyle G, Hand J, Mandalia S, Boffito M, Nelson M & Gazzard B. Early virological failure in HIV-infected subjects on didanosine-tenofovir-efavirenz: 12 week results from a ranzomized trial. AIDS 2005; 19:1183-1188.
28. Podzamczer D, Ferrer E & Gatell JM. Early virological failure with a combination of tenofovir, didanosine and efavirenz. Antiviral Therapy 2005; 10:171-177.
29. Torti C, Quiros-Roldan E, Regazzi M, Antinori A, Patroni A, Villani P, Tirelli V, Cologni G, Zinzi D, Lo Caputo S, Perini P & Carosi G. Early virological failure after tenofovir + didanosine + efavirenz combination in HIV-positive patients upon starting antiretroviral therapy. Antiviral Therapy 2005; 10:505-513.
30. Clarke S, Mulcahy F, Tjia J, Reynolds H, Gibbons S, Barry M & Back D. The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside inhibitor efavirenz. British Journal of Clinical Pharmacology. 2001; 51:213-217.
31. Barrios A, Garcia-Benayas T, Gonzalez-Lahoz J & Soriano V. Tenofovir-related nephrotoxicity in HIV-infected patients. AIDS 2004; 18:960-963.
32. Negredo E, Molto J, Burger D, Viciana P, Ribera E, Paredes R & Clotet B. Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir based regimens despite undetectable viral load. AIDS 2004; 18:459-463.
33. + T cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine. AIDS 2005; 19:569-575.
34. Stein J. Managing cardiovascular risk in patients with HIV infection. Journal of Acquired Immune Deficiency Syndromes 2005; 38:115-123.